Summary
Pfizer Inc.'s 2019 Form 10-K, filed in early 2020, highlights a company in significant transition, focusing on a strategic shift towards a more streamlined, innovation-focused biopharmaceutical business. Key strategic moves include the formation of a consumer healthcare joint venture with GSK and the pending combination of its Upjohn business with Mylan to create Viatris. These actions signal a move away from diverse business lines to concentrate on innovative medicines. For investors, the report underscores the importance of the Biopharma segment, which comprises six key business units, and notes the significant revenue contribution from major products like Prevnar 13, Ibrance, and Eliquis. However, the company also faces substantial risks related to patent expirations, increasing generic competition (particularly with the recent loss of exclusivity for Lyrica), and pricing pressures in global markets. The company's R&D investment remains a critical component for future growth, with a pipeline focused on oncology, immunology, rare diseases, and vaccines.
Financial Highlights
56 data points| Revenue | $40.91B |
| Cost of Revenue | $8.05B |
| Gross Profit | $32.85B |
| SG&A Expenses | $12.73B |
| Operating Income | $10.71B |
| Interest Expense | $1.57B |
| Net Income | $16.03B |
| EPS (Basic) | $2.88 |
| EPS (Diluted) | $2.82 |
| Shares Outstanding (Basic) | 5.57B |
| Shares Outstanding (Diluted) | 5.67B |
Key Highlights
- 1Pfizer is undergoing a strategic transformation to become a more focused, global leader in science-based innovative medicines, evidenced by the formation of a consumer healthcare JV with GSK and the pending combination of Upjohn with Mylan (Viatris).
- 2The Biopharma segment is central to Pfizer's strategy, encompassing six key business units: Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines, and Internal Medicine.
- 3Significant business development activities in 2019 included the acquisition of Array BioPharma for $11.2 billion and a licensing agreement with Akcea Therapeutics for a cardiovascular therapy.
- 4The company faces substantial risks from patent expirations and increasing generic competition, notably the loss of U.S. patent protection for Lyrica in June 2019, leading to multi-source generic competition.
- 5Pfizer continues to invest heavily in Research & Development, with priorities focused on delivering a pipeline of differentiated medicines and vaccines across key therapeutic areas.
- 6International operations represent a significant portion of revenue (54% in 2019), but are subject to risks including currency fluctuations and government-imposed pricing constraints.
- 7The company is actively managing financial risks, including foreign exchange and interest rate exposure, and is subject to extensive government regulation in its operating markets worldwide.